Triple negative breast cancer (TNBC) affects women of African descent three times more than women of European descent. African American women with TNBC have poor survival and high mortality rates. Metastasis to distant vital organs such as bone, lung, and brain is the most devastating feature of TNBC. It is critical to investigate the molecular mechanism(s) that lead to aggressive disease in patients with TNBC so that improved therapeutic options can be developed. Emerging evidence suggests that tumor-derived exosomes are mediators of tumorigenesis and tissue-specific metastasis by contributing to the establishment of a pre- metastatic niche. Annexin A2 (AnxA2) is an often identified exosomal protein whose elevated levels are seen in TNBC patient sera and cell lines. Exosomal AnxA2 (exo-AnxA2) is more highly expressed in African American (AA) TNBC patients than in Caucasian TNBC patients resulting in reduced survival. Our recent data suggest a role for exo-AnxA2 in establishing a pre-metastatic niche which subsequently promotes breast cancer metastasis. The long-term goal of our research is to develop improved therapeutic options for aggressive TNBC that disproportionately affects AA patients. Our hypothesis for the proposed studies is that exo-AnxA2 is a determinant of the aggressiveness of TNBC metastasis and contributes to poor prognosis in AA patients with TNBC. The premise for this hypothesis stems from the literature (2, 6-9,11) and our published data indicating that exo-AnxA2 creates a pre-metastatic niche that may drive aggressive TNBC metastasis. We will address this hypothesis by the following three specific aims:
Aim 1 : Evaluate differences in the association of exo-AnxA2 expression with measures of disease aggressiveness among racially distinct populations.
Aim 2 : Determine whether exo-AnxA2 promotes aggressive TNBC metastasis.
Aim 3 : Determine the mechanism(s) that drives exo-AnxA2-mediated metastatic niche formation and aggressive tumors in TNBC. The impact of the proposed studies is the likely identification of a novel secreted and exosomal protein as a functional regulator of long-range communications between metastatic tumors and the target stromal microenvironment. Moreover, due to their extracellular location, secreted AnxA2 and partner proteins represent potential prognostic agents and therapeutic targets. Thus, we expect this research to open up exciting new avenues of clinical translation in metastasis detection, prognosis, and therapy for TNBC patients.
Triple negative breast cancer is a significant health disparity in African American women. There is an urgent need to develop novel therapeutic strategies. Successful completion of this project will provide an innovative and novel treatment option for triple negative breast cancer patients who are very likely to develop metastatic disease.
|Gibbs, Lee D; Chaudhary, Pankaj; Mansheim, Kelsey et al. (2018) ANXA2 expression in African American triple-negative breast cancer patients. Breast Cancer Res Treat :|
|Gibbs, Lee D; Vishwanatha, Jamboor K (2018) Prognostic impact of AnxA1 and AnxA2 gene expression in triple-negative breast cancer. Oncotarget 9:2697-2704|